We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,778.00 | 1,773.50 | 1,774.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.82 | 73.04B |
By Josh Beckerman
AnaptysBio Inc. shares rose 10% to $27.72 after hours as a second approved indication for a GlaxoSmithKline PLC drug will result in a $20 million milestone payment.
The U.S. Food and Drug Administration approved GSK's Jemperli for the treatment of adult patients with mismatch repair deficient recurrent or advanced solid tumors.
Jemperli was generated by AnaptysBio and subsequently developed by Tesaro Inc., which GSK bought in early 2019.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 17, 2021 18:36 ET (22:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions